RxDoctor Payments Data

Lubna Siddiki, MD

Psychiatry · Frisco, TXNPI 1497700942

Payments from drug & device makers

$7,593in general payments, 2019–2025

Across 271 payments — averaging $28.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neuronetics, Inc.$3K
  • Johnson & Johnson$768
  • AbbVie$729
  • Otsuka America Pharmaceutical, Inc.$533
  • Alkermes, Inc.$435
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$408
  • plus $2K from 21 others

What the payments were for

  • Travel & lodging$1,55220%
  • Food & beverage$6,00279%
  • Education$391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,593 in reported general payments places this provider in the 85th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$134,344
Medicare patients
83
Services billed
1,099

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole11$31,182
VraylarCariprazine Hcl14$27,282
CaplytaLumateperone Tosylate11$16,989
TrintellixVortioxetine Hydrobromide12$13,381
Aripiprazole136$8,999
Lurasidone Hcl62$8,245
Paliperidone ErPaliperidone23$5,288
Bupropion XlBupropion Hcl239$3,820
Duloxetine Hcl182$3,166
Divalproex Sodium ErDivalproex Sodium24$2,396
Desvenlafaxine Succinate ErDesvenlafaxine Succinate46$2,368
Ziprasidone Hcl30$1,872
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine32$1,410
Mirtazapine95$1,302
Clonazepam158$1,268

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$533$31,18211 claims
AbbVieVraylar$729$27,28214 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$408$16,98911 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$306$13,38112 claims
Almatica Pharma LLCSertraline Hcl$22$31456 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in Frisco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →